Every 10-Q that Aspen Aerogels, Inc. (ASPN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ASPN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASPN filings page.
Aspen Aerogels, Inc. reported significantly lower results for the quarter and six months ended June 30, 2026. Revenue declined to $49.8 million in Q2 and $87.7 million year‑to‑date, from $78.0 million and $156.7 million in the prior‑year periods, with both Thermal Barrier and Energy Industrial sales down.
Gross profit fell to $3.3 million for Q2 and $7.5 million year‑to‑date, and the company recorded net losses of $23.3 million in Q2 and $47.0 million for the first half, narrower than the prior year, which included large Statesboro plant impairment charges.
At June 30, 2026, Aspen held $151.7 million of cash and cash equivalents, generated $17.9 million of operating cash in the first half, and carried a $79.5 million term loan and $10.9 million drawn on its revolving facility. A $37.6 million settlement with a large Thermal Barrier customer is being recognized as revenue over about two years, contributing to $35.3 million of deferred revenue. The company also booked an $8.9 million loss on damaged assets and a matching insurance receivable from East Providence incidents, and stated that existing cash should support operations for at least twelve months, while long‑term growth is expected to require additional financing.
Aspen Aerogels reported a sharp revenue decline and a smaller loss for the quarter. Revenue for the three months ended March 31, 2026 fell to $37.9 million, down 52% from $78.7 million a year earlier, mainly from lower thermal barrier sales.
Net loss narrowed to $23.7 million (basic and diluted loss per share of $0.29) from $301.2 million ($3.67 per share), as the prior period included a large impairment related to the cancelled Statesboro plant. Aspen generated $34.1 million of cash from operations and ended the quarter with $173.9 million in cash and cash equivalents.
Deferred revenue rose to $36.6 million, helped by a $37.6 million customer settlement that is being recognized over about two years. After quarter-end, an explosion at the East Providence, Rhode Island plant halted operations; the company is relying on inventory, an external manufacturing facility and insurance while working to restart the site.
Aspen Aerogels (ASPN) filed its Q3 2025 10‑Q, showing a sharp year-over-year contraction. Q3 revenue was $73,017, down from $117,340, with gross profit of $20,799 versus $49,043. The quarter swung to an operating loss of $3,348 and a net loss of $6,334.
For the nine months, revenue was $229,764 versus $329,611 last year, and net loss reached $316,639, primarily due to a $287,567 impairment tied to ceasing construction of the Statesboro, Georgia plant. Total assets fell to $491,395 from $895,144 at year-end, while stockholders’ equity declined to $305,733.
Cash and cash equivalents were $150,722. Debt included a term loan of $99,000 and a revolving balance of $14,252; availability under the revolver was $26.8 million. Two customers represented 72% of year-to-date revenue, and one customer accounted for 69% of accounts receivable. Management states it is in compliance with amended MidCap covenants as of September 30, 2025, but notes no assurance of compliance at the end of Q4 2025.